As inflammation is increasingly considered to play a role in TRD, cyclooxygenase-2 inhibitors (COX-2 inhibitors) were initially the emphasis of anti-inflammatory research in TRD as augmentation options. Here, PTGS2 is linked to treatment resistant depression.